Eisai starts two phase III studies for antiepileptic drug perampanel

Eisai has started two phase III clinical studies for its in-house-discovered antiepileptic drug (AED) perampanel (generic name: perampanel hydrate, product name: Fycompa) as adjunctive therapy in pedi…
Read the full story: PBR - Clinical Trials News